ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 851

An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis

James R. Seibold1, Christopher P. Denton2, Ekkehard Grünig3, Diana Bonderman4, Oliver Distler5, Dinesh Khanna6, Ulf Müller-Ladner7, Janet E. Pope8, Madelon C. Vonk9, Martin Doelberg10, Harbajan Chadha-Boreham10, Harald Heinzl4, Daniel M. Rosenberg10, Vallerie McLaughlin11 and John G. Coghlan12, 1Scleroderma Research Consultants LLC, Avon, CT, 2Department of Rheumatology, Royal Free Hospital, London, United Kingdom, 3University Hospital, Heidelberg, Germany, 4Medical University of Vienna, Vienna, Austria, 5Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 7Abt. f. Rheumatologie u. klinische Immunologie, Osteologie, Physikalische Therapie, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 8Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 9Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 10Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 11Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, 12Royal Free Hospital, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Pulmonary complications and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality and late-stage morbidity in systemic sclerosis (SSc). Current PAH screening recommendations are consensus-based and their clinical application results in high false positive rates. The rate of missed diagnoses has never been determined. The DETECT study aimed to develop an evidence-based screening algorithm for PAH in SSc patients that would limit the number of missed PAH diagnoses.

Methods: In this prospective, multicenter, cross-sectional observational cohort study [NCT00706082], adult patients with SSc for >3 years, a diffusing capacity of the lung for carbon monoxide (DLCO) <60% of predicted, and no previous diagnosis of pulmonary hypertension underwent multiple non-invasive screening tests followed by diagnostic right heart catheterization (RHC). Univariable and multivariable analyses selected the best discriminatory variables for identifying PAH, which were assessed for clinical plausibility and feasibility and incorporated into a two-step internally validated screening algorithm.

Results: Of 466 SSc patients, 19% (n=87) had RHC-confirmed PAH and 69% (n=321) had normal pulmonary arterial pressure (PAP). PAH was mild (mean PAP 32.5 [30.7-34.3] mm Hg; 64.4% WHO functional class I or II). Six simple screening tests (forced vital capacity [% predicted]/DLCO [% predicted]; current/past telangiectasias; anti-centromere antibody; N-terminal pro-brain natriuretic peptide; uric acid; right axis deviation on electrocardiography) were used in step 1 of the algorithm to derive a risk prediction score with pre-defined high sensitivity (to minimize the rate of missed PAH diagnoses) and to inform a decision to refer to echocardiography. Right atrial area and tricuspid regurgitation jet velocity were added in step 2 (with pre-defined low specificity) to determine referral to RHC. The DETECT algorithm, with step 1 sensitivity 97% and step 2 specificity 35%, resulted in a rate of missed PAH diagnoses of 4% requiring RHC in 62% of patients. When the current ERS/ESC screening recommendations were applied, the missed diagnoses and the RHC referral rates were 29% and 40%, respectively.

Conclusion: The two-step algorithm is a sensitive non-invasive screening tool for detection of PAH in SSc which addresses resource utilization of RHC, identifies less advanced disease and, most importantly, minimizes missed diagnoses. This is an evidence-based approach to revise standards of care in SSc patients.


Disclosure:

J. R. Seibold,

Actelion Pharmaceuticals EU,

5,

United Therapeutics,

5,

United Therapeutics,

8,

Bayer Pharmaceuticals,

5,

Intermune,

5,

Boehringer Ingelheim,

5,

Fibrogen,

5,

Pfizer Inc,

5,

Sanofi-Aventis Pharmaceutical,

5;

C. P. Denton,

Actelion Pharmaceuticals Ltd, Pfizer, GSK, United Therapeutics,

5,

Actelion Pharmaceuticals Ltd, Pfizer, GSK, United Therapeutics,

2,

Actelion Pharmaceuticals Ltd, Pfizer, GSK, United Therapeutics,

8;

E. Grünig,

Actelion Pharmaceuticals Ltd, Pfizer, GSK, Bayer, Encysive, Lilly,

2,

Actelion Pharmaceuticals Ltd, Bayer, Gilead, GSK, Lilly, Milteney, Novartis, Pfizer, Rotex Medica,

5,

Actelion Pharmaceuticals Ltd, Bayer, Gilead, GSK, Lilly, Milteney, Novartis, Pfizer, Rotex Medica,

8;

D. Bonderman,

Actelion Pharmaceuticals Ltd,

5;

O. Distler,

Actelion, Pfizer, Boehringer-Ingelheim, Bayer, Roche, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Novartis and Active Biotec,

2,

Actelion, Pfizer, Boehringer-Ingelheim, Bayer, Roche, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Novartis and Active Biotec,

5,

Actelion, Pfizer and Ergonex,

8;

D. Khanna,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

2,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

5,

Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,

8;

U. Müller-Ladner,

Actelion Pharmaceuticals Ltd,

5;

J. E. Pope,

Actelion and Pfizer,

2,

Actelion and Pfizer,

5;

M. C. Vonk,

Actelion, Pfizer, GSK, United Therapeutics,

2,

Actelion, Pfizer, GSK, United Therapeutics,

5,

Actelion, Pfizer, GSK, United Therapeutics,

8;

M. Doelberg,

Actelion Pharmaceuticals Ltd,

1,

Actelion Pharmaceuticals Ltd,

3;

H. Chadha-Boreham,

Actelion Pharmaceuticals Ltd,

1,

Actelion Pharmaceuticals Ltd,

3;

H. Heinzl,

Actelion Pharmaceuticals Ltd and Roche Austria,

2,

Actelion Pharmaceuticals Ltd,

5;

D. M. Rosenberg,

Actelion Pharmaceuticals Ltd,

1,

Actelion Pharmaceuticals Ltd,

3;

V. McLaughlin,

Actelion, Bayer, Gilead, United Therapeutics,

5,

Actelion, Bayer, Novartis, United Therapeutics,

2;

J. G. Coghlan,

Actelion Pharmaceuticals Ltd, Pfizer, GSK, United Therapeutics,

2,

Actelion Pharmaceuticals Ltd, Pfizer, GSK, United Therapeutics,

5,

Actelion Pharmaceuticals Ltd, Pfizer, GSK, United Therapeutics,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-evidence-based-screening-algorithm-for-pulmonary-arterial-hypertension-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology